Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo

Publication Date:
2018-06-16
Publisher:
The American Association for Cancer Research (AACR)
Print ISSN:
1078-0432
Electronic ISSN:
1557-3265
Topics:
Medicine
Published by:
_version_ 1836398973113335808
autor Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
beschreibung Purpose: Checkpoint kinase 1 inhibitors (CHEK1i) have single-agent activity in vitro and in vivo . Here, we have investigated the molecular basis of this activity. Experimental Design: We have assessed a panel of melanoma cell lines for their sensitivity to the CHEK1i GNE-323 and GDC-0575 in vitro and in vivo . The effects of these compounds on responses to DNA replication stress were analyzed in the hypersensitive cell lines. Results: A subset of melanoma cell lines is hypersensitive to CHEK1i-induced cell death in vitro , and the drug effectively inhibits tumor growth in vivo . In the hypersensitive cell lines, GNE-323 triggers cell death without cells entering mitosis. CHEK1i treatment triggers strong RPA2 hyperphosphorylation and increased DNA damage in only hypersensitive cells. The increased replication stress was associated with a defective S-phase cell-cycle checkpoint. The number and intensity of pRPA2 Ser4/8 foci in untreated tumors appeared to be a marker of elevated replication stress correlated with sensitivity to CHEK1i. Conclusions: CHEK1i have single-agent activity in a subset of melanomas with elevated endogenous replication stress. CHEK1i treatment strongly increased this replication stress and DNA damage, and this correlated with increased cell death. The level of endogenous replication is marked by the pRPA2Ser4/8 foci in the untreated tumors, and may be a useful marker of replication stress in vivo . Clin Cancer Res; 24(12); 2901–12. ©2018 AACR .
citation_standardnr 6284481
datenlieferant ipn_articles
feed_id 9363
feed_publisher The American Association for Cancer Research (AACR)
feed_publisher_url http://www.aacr.org/
insertion_date 2018-06-16
journaleissn 1557-3265
journalissn 1078-0432
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher The American Association for Cancer Research (AACR)
quelle Clinical Cancer Research
relation http://clincancerres.aacrjournals.org/cgi/content/short/24/12/2901?rss=1
search_space articles
shingle_author_1 Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
shingle_author_2 Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
shingle_author_3 Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
shingle_author_4 Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
shingle_catch_all_1 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
Purpose: Checkpoint kinase 1 inhibitors (CHEK1i) have single-agent activity in vitro and in vivo . Here, we have investigated the molecular basis of this activity. Experimental Design: We have assessed a panel of melanoma cell lines for their sensitivity to the CHEK1i GNE-323 and GDC-0575 in vitro and in vivo . The effects of these compounds on responses to DNA replication stress were analyzed in the hypersensitive cell lines. Results: A subset of melanoma cell lines is hypersensitive to CHEK1i-induced cell death in vitro , and the drug effectively inhibits tumor growth in vivo . In the hypersensitive cell lines, GNE-323 triggers cell death without cells entering mitosis. CHEK1i treatment triggers strong RPA2 hyperphosphorylation and increased DNA damage in only hypersensitive cells. The increased replication stress was associated with a defective S-phase cell-cycle checkpoint. The number and intensity of pRPA2 Ser4/8 foci in untreated tumors appeared to be a marker of elevated replication stress correlated with sensitivity to CHEK1i. Conclusions: CHEK1i have single-agent activity in a subset of melanomas with elevated endogenous replication stress. CHEK1i treatment strongly increased this replication stress and DNA damage, and this correlated with increased cell death. The level of endogenous replication is marked by the pRPA2Ser4/8 foci in the untreated tumors, and may be a useful marker of replication stress in vivo . Clin Cancer Res; 24(12); 2901–12. ©2018 AACR .
Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_2 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
Purpose: Checkpoint kinase 1 inhibitors (CHEK1i) have single-agent activity in vitro and in vivo . Here, we have investigated the molecular basis of this activity. Experimental Design: We have assessed a panel of melanoma cell lines for their sensitivity to the CHEK1i GNE-323 and GDC-0575 in vitro and in vivo . The effects of these compounds on responses to DNA replication stress were analyzed in the hypersensitive cell lines. Results: A subset of melanoma cell lines is hypersensitive to CHEK1i-induced cell death in vitro , and the drug effectively inhibits tumor growth in vivo . In the hypersensitive cell lines, GNE-323 triggers cell death without cells entering mitosis. CHEK1i treatment triggers strong RPA2 hyperphosphorylation and increased DNA damage in only hypersensitive cells. The increased replication stress was associated with a defective S-phase cell-cycle checkpoint. The number and intensity of pRPA2 Ser4/8 foci in untreated tumors appeared to be a marker of elevated replication stress correlated with sensitivity to CHEK1i. Conclusions: CHEK1i have single-agent activity in a subset of melanomas with elevated endogenous replication stress. CHEK1i treatment strongly increased this replication stress and DNA damage, and this correlated with increased cell death. The level of endogenous replication is marked by the pRPA2Ser4/8 foci in the untreated tumors, and may be a useful marker of replication stress in vivo . Clin Cancer Res; 24(12); 2901–12. ©2018 AACR .
Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_3 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
Purpose: Checkpoint kinase 1 inhibitors (CHEK1i) have single-agent activity in vitro and in vivo . Here, we have investigated the molecular basis of this activity. Experimental Design: We have assessed a panel of melanoma cell lines for their sensitivity to the CHEK1i GNE-323 and GDC-0575 in vitro and in vivo . The effects of these compounds on responses to DNA replication stress were analyzed in the hypersensitive cell lines. Results: A subset of melanoma cell lines is hypersensitive to CHEK1i-induced cell death in vitro , and the drug effectively inhibits tumor growth in vivo . In the hypersensitive cell lines, GNE-323 triggers cell death without cells entering mitosis. CHEK1i treatment triggers strong RPA2 hyperphosphorylation and increased DNA damage in only hypersensitive cells. The increased replication stress was associated with a defective S-phase cell-cycle checkpoint. The number and intensity of pRPA2 Ser4/8 foci in untreated tumors appeared to be a marker of elevated replication stress correlated with sensitivity to CHEK1i. Conclusions: CHEK1i have single-agent activity in a subset of melanomas with elevated endogenous replication stress. CHEK1i treatment strongly increased this replication stress and DNA damage, and this correlated with increased cell death. The level of endogenous replication is marked by the pRPA2Ser4/8 foci in the untreated tumors, and may be a useful marker of replication stress in vivo . Clin Cancer Res; 24(12); 2901–12. ©2018 AACR .
Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_4 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
Purpose: Checkpoint kinase 1 inhibitors (CHEK1i) have single-agent activity in vitro and in vivo . Here, we have investigated the molecular basis of this activity. Experimental Design: We have assessed a panel of melanoma cell lines for their sensitivity to the CHEK1i GNE-323 and GDC-0575 in vitro and in vivo . The effects of these compounds on responses to DNA replication stress were analyzed in the hypersensitive cell lines. Results: A subset of melanoma cell lines is hypersensitive to CHEK1i-induced cell death in vitro , and the drug effectively inhibits tumor growth in vivo . In the hypersensitive cell lines, GNE-323 triggers cell death without cells entering mitosis. CHEK1i treatment triggers strong RPA2 hyperphosphorylation and increased DNA damage in only hypersensitive cells. The increased replication stress was associated with a defective S-phase cell-cycle checkpoint. The number and intensity of pRPA2 Ser4/8 foci in untreated tumors appeared to be a marker of elevated replication stress correlated with sensitivity to CHEK1i. Conclusions: CHEK1i have single-agent activity in a subset of melanomas with elevated endogenous replication stress. CHEK1i treatment strongly increased this replication stress and DNA damage, and this correlated with increased cell death. The level of endogenous replication is marked by the pRPA2Ser4/8 foci in the untreated tumors, and may be a useful marker of replication stress in vivo . Clin Cancer Res; 24(12); 2901–12. ©2018 AACR .
Oo, Z. Y., Stevenson, A. J., Proctor, M., Daignault, S. M., Walpole, S., Lanagan, C., Chen, J., Skalamera, D., Spoerri, L., Ainger, S. A., Sturm, R. A., Haass, N. K., Gabrielli, B.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_title_1 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
shingle_title_2 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
shingle_title_3 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
shingle_title_4 Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
timestamp 2025-06-30T23:35:35.060Z
titel Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
titel_suche Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo
topic WW-YZ
uid ipn_articles_6284481